<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene K444N literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.K444N</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Highly resistant to mAb SARS2-01 and moderately resistant to 2H04 of 10 antibodies tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> ~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.<br/> (<a href="https://doi.org/10.1101/2021.03.22.436481" class="lit_link">Sun et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Abolishes binding efficiency vs wild type for mAb REGN10933.<br/> (<a href="https://doi.org/10.1126/science.abf4830" class="lit_link">Rappazzo et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Improvement in neutralization capability of all 4 convalescent sera tested.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Positive selection (up to 14% of supernatant sequences) after COV-NY convalescent plasma assay (<a href="https://doi.org/10.1101/2020.07.21.214759" class="lit_link">Weisblum et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron (B.1.1.529 [BA.1]) RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes under no vaccination results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 1/2 mRNA vaccines results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inhibition of Omicron BA.2 RBD point mutant pseudotypes due to 3 mRNA vaccine doses results in high relative infection for this mutation, for individuals previously infected.<br/> (<a href="https://doi.org/10.1101/2022.08.17.504313" class="lit_link">Witte et al. (2022)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
